EUVIMEDEUVIMED entdecken
Crossref

Secondary prevention and management of dyslipidaemia in patients with coronary artery disease on statin therapy in a tertiary academic centre in Johannesburg

Patience Ntila, Dineo Mpanya, Nqoba Tsabedze

Cardiovascular Journal of Africa · 2025

DOI: 10.5830/cvja-2025-035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Journal of Africa, 2025. Verfasst von Patience Ntila und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand and…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Coronary Artery Disease, Tertiary Care Centers.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Optimal low-density lipoprotein cholesterol (LDL-C) control in patients with established atherosclerotic cardiovascular disease (ASCVD) is defined as LDL-C levels less than 1.4 mmol/L and a reduction of ≥ 50% in baseline LDL-C levels. This study aims to assess LDL-C control in patients with ASCVD on statin treatment in a tertiary academic hospital. We conducted a cross-sectional study on patients with ASCVD on statin therapy and compared LDL-C levels at the time of presentation with coronary syndromes with the most recent LDL-C obtained during follow-up visits. There were 458 patients with coronary syndromes. After a median duration of 17 months (interquartile range [IQR]: 7-31), 93 (20.3%) patients had optimal LDL-C control. A history of previous coronary artery disease or stroke (odds ratio [OR]: 1.73; 95% confidence interval [CI]: 1.05-2.85; p = 0.031) increased the risk of poor LDL-C control. Only 20.3% of patients with ASCVD on statins achieved the guideline-recommended LDL-C target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsDyslipidemiasCoronary Artery DiseaseTertiary Care CentersCholesterol, LDLSecondary PreventionHumansFemaleMaleCross-Sectional StudiesMiddle AgedBiomarkersRisk FactorsTreatment OutcomeSouth AfricaAgedTime FactorsAcademic Medical Centers

Stichwörter der Autor:innen

Africacholesterolcoronary artery diseasedyslipidaemialow‐density lipoproteins

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLBiomarkers

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand and the Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, So…

Zitieren

APA

Ntila, P., Mpanya, D., & Tsabedze, N. (2025). Secondary prevention and management of dyslipidaemia in patients with coronary artery disease on statin therapy in a tertiary academic centre in Johannesburg. Cardiovascular Journal of Africa. https://doi.org/10.5830/cvja-2025-035

Vancouver

Ntila P, Mpanya D, Tsabedze N. Secondary prevention and management of dyslipidaemia in patients with coronary artery disease on statin therapy in a tertiary academic centre in Johannesburg. Cardiovascular Journal of Africa. 2025. doi:10.5830/cvja-2025-035

BibTeX
@article{Ntila2025,
  author = {Ntila, Patience and Mpanya, Dineo and Tsabedze, Nqoba},
  title = {Secondary prevention and management of dyslipidaemia in patients with coronary artery disease on statin therapy in a tertiary academic centre in Johannesburg},
  journal = {Cardiovascular Journal of Africa},
  year = {2025},
  doi = {10.5830/cvja-2025-035}
}
Kostenlos starten →